| Literature DB >> 35198096 |
Monica Butnariu1, Cristina Quispe2, Jesús Herrera-Bravo3,4, Javad Sharifi-Rad5, Laxman Singh6, Nora M Aborehab7, Abdelhakim Bouyahya8, Alessandro Venditti9, Surjit Sen10,11, Krishnendu Acharya10, Moein Bashiry12, Shahira M Ezzat13,14, William N Setzer15, Miquel Martorell16, Ksenija S Mileski17, Iulia-Cristina Bagiu18,19, Anca Oana Docea20, Daniela Calina21, William C Cho22.
Abstract
Crocus species are mainly distributed in North Africa, Southern and Central Europe, and Western Asia, used in gardens and parks as ornamental plants, while Crocus sativus L. (saffron) is the only species that is cultivated for edible purpose. The use of saffron is very ancient; besides the use as a spice, saffron has long been known also for its medical and coloring qualities. Due to its distinctive flavor and color, it is used as a spice, which imparts food preservative activity owing to its antimicrobial and antioxidant activity. This updated review discusses the biological properties of Crocus sativus L. and its phytoconstituents, their pharmacological activities, signaling pathways, and molecular targets, therefore highlighting it as a potential herbal medicine. Clinical studies regarding its pharmacologic potential in clinical therapeutics and toxicity studies were also reviewed. For this updated review, a search was performed in the PubMed, Science, and Google Scholar databases using keywords related to Crocus sativus L. and the biological properties of its phytoconstituents. From this search, only the relevant works were selected. The phytochemistry of the most important bioactive compounds in Crocus sativus L. such as crocin, crocetin, picrocrocin, and safranal and also dozens of other compounds was studied and identified by various physicochemical methods. Isolated compounds and various extracts have proven their pharmacological efficacy at the molecular level and signaling pathways both in vitro and in vivo. In addition, toxicity studies and clinical trials were analyzed. The research results highlighted the various pharmacological potentials such as antimicrobial, antioxidant, cytotoxic, cardioprotective, neuroprotective, antidepressant, hypolipidemic, and antihyperglycemic properties and protector of retinal lesions. Due to its antioxidant and antimicrobial properties, saffron has proven effective as a natural food preservative. Starting from the traditional uses for the treatment of several diseases, the bioactive compounds of Crocus sativus L. have proven their effectiveness in modern pharmacological research. However, pharmacological studies are needed in the future to identify new mechanisms of action, pharmacokinetic studies, new pharmaceutical formulations for target transport, and possible interaction with allopathic drugs.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35198096 PMCID: PMC8860555 DOI: 10.1155/2022/8214821
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1The main phytoconstituents of Crocus sativus L. and their pharmacological properties.
In vitro biological activities of Crocus plants.
| Extract/compound | Tested cell lines/methods of analysis | Effect/mechanisms | Ref. |
|---|---|---|---|
|
| |||
| Saffron/aqueous extract | A549 lung cancer cells | IC50 = 390 | [ |
| Crocin/aqueous extract | MCF-7 breast cancer cells | IC50 = 3.5 mg/mL | [ |
| Saffron and its derivatives/ethanolic extract | HeLa human cervical epithelioid carcinoma cells | IC50 = 2.3 mg/mL for saffron, IC50 = 3 mM for crocin, IC50 = 0.8 mM for safranal, and IC50 = 3 mM for picrocrocin | [ |
| Saffron | HeLa human cervical epithelioid carcinoma cells colony formation inhibitory assay | ↓tumor cell growth | [ |
| Crocin | HL-60 leukaemia cells | IC50 = 0.625 − 10 mg/mL | [ |
| Saffron juice | Caco-2 colon cancer cells | IC50 = 50 | [ |
| Saffron/aqueous extract | MCF-7 breast cancer cells gene expression level of MMP using RT PCR trypan blue test | ↓MMP gene expression | [ |
|
| |||
|
| Agar well diffusion | Petroleum ether extract: effective against | [ |
|
| Agar well diffusion | The extract that contained the glycosidic part of flavonoids exhibited weak antimicrobial activity | [ |
| Saffron/aqueous extract | Modified well plate test | ↓growth inhibition zone tested pathogens: | [ |
|
| |||
|
| DPPH reductive potentials, metal chelating phosphomolybdenum method | The water extract showed the most powerful antioxidant activity | [ |
| Crocin, saffron/ethanolic extract | Antihemolysis activity | The saffron extract exhibited 107 mg | [ |
| Saffron/ethanolic, methanolic extract | DPPH ferric reducing antioxidant power | Methanolic extract 300 | [ |
| Saffron/corms, tepals, and leaves |
| The best antioxidant activity: leaves and tepal extract, the least antioxidant activity: corms | [ |
| Saffron/aqueous extract | Bronchial epithelial cells | ↓NO, ↓iNOS, and ↓peroxynitrite ion generation | [ |
|
| |||
|
|
|
| [ |
Abbreviations and symbols: ↑ increased, ↓ decreased, 2,2-diphenyl-1-picryl-hydrazyl-hydrate (DPPH), induced nitric oxide synthase (iNOS), nitric oxide (NO), and poly (ADP-ribose) polymerase (PARP).
In vivo evaluation of the pharmacological properties of Crocus plant.
| Plant/compound/extract | Doses | Route | Model | Main pharmacological effect | Ref. |
|---|---|---|---|---|---|
| Crocetin | 100 mg/kg | Oral | Rats stroke-prone spontaneously hypertensive rats high-oxidative stress model | Antioxidant | [ |
|
| 10, 20, and 40 mg/kg | i.p. | Rats | Antihyperglycemic | [ |
|
| 500 mg/kg | i.v. | Rats, guinea pigs | Antihypertensive | [ |
| Crocetin | 20 mg/kg | Oral | Lung cancer-bearing mice benzo(a)pyrene- (B(a)p-) induced lung carcinoma | Antitumor | [ |
| Crocetin | 50 mg/kg | i.p. | Mice | Antitumor | [ |
| Zhejiang saffron | 100 mg/kg | Oral | Mice | Antitumor | [ |
| Saffron/aqueous infusion | 50-500 mg/kg | Oral | Mice | Antitumor | [ |
| Saffron/aqueous extract | 100 mg/kg | Topical | Mice | Antitumor | [ |
| Saffron | 400, 800 mg/kg | Oral | Rats | Anticonvulsant | [ |
| Safranal | 0.15, 0.35 mL/kg | i.p. | Mice | Anticonvulsant | [ |
| Safranal | 72.75, 145.5, and 290 mg/kg | i.p. | Rats | Anticonvulsant | [ |
| Crocin | 200 mg/kg | i.p. | Mice | It did not show anticonvulsant activity | [ |
|
| 50 mg/kg | Oral | Meriones shawi | Neuroprotective | [ |
| Crocetin | 25, 50, 75 | i.p. | Rats | Neuroprotective | [ |
| Saffron | 0.01% | Oral | BALB-c mice | Neuroprotective | [ |
|
| 100 mg/kg | Oral | Rats | Neuroprotective | [ |
| Saffron/honey syrup | 200, 500 mg/kg | Oral | Mice | Neuroprotective | [ |
| Saffron/aqueous extract | 50, 100, 200 mg/kg | Oral | Rats | Neuroprotective | [ |
| Crocin | 30, 60, 120 mg/kg | Oral | Rats | Neuroprotective | [ |
| Crocetin | 50 mg/kg | Oral | Rats | Neuroprotective | [ |
| Crocin | 25, 50 mg/kg | i.p. | Rats | Retinal damage protection | [ |
| Crocetin | 100 mg/kg | Oral | Mice | Retinal damage protection | [ |
| Saffron/aqueous extract | 50, 100, 150, and 250 mg/kg | i.p. | Rats | Effect on brain neurotransmitters | [ |
| Saffron/aqueous, ethanolic extracts | 80–320, 400–800 mg/kg | i.p. | Mice | Effect on opioid system | [ |
| Saffron/ethanolic extract safranal | 10, 50, and 100 mg/kg | i.p. | Mice | Effect on opioid system | [ |
| Crocin | 400, 600 mg/kg | i.p. | Mice | Effect on opioid system | [ |
|
| 5, 10 | Intra-accumbal | Rats | Effect on opioid system | [ |
|
| Extracts 0.2-0.8 g/kg | i.p. | Mice | Antidepressant | [ |
|
| 30 mg/kg | ICV | Rats | Anti-Alzheimer | [ |
| Saffron | 60 mg/kg | i.p. | BALB-c mice adult and aged | Cognitive enhancing effect | [ |
| Crocin | 30 mg/kg | ICV | Rats | Anti-Alzheimer | [ |
| Crocin | 25-100 mg/kg | Oral | Rats |
| [ |
| Crocin safranal | 25, 50, and 100 mg/kg | i.p.l. | Rats | Anti-inflammatory | [ |
|
| 20, 40, and 80 mg/kg | Oral | Rats | Antihyperglycemic | [ |
| Safranal | 0.2, 0.5, 0.75 mL/kg | Aerosol | Guinea pigs' citric acid aerosol for 10 min | Antitussive | [ |
Abbreviations and symbols: ↑ increase, ↓ decrease, body weight (bw), catalase (CAT), dimethylbenzene [a] anthracene (DMBA), dorsal striatum (DS), generalized tonic-clonic seizures (GTCS), intracerebroventricular (ICV), intraperitoneal (i.p.), intraplantar (i.p.l.), intravenously (i.v.), locus coeruleus (LC), 20-methylcholanthrene (MCA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), malondialdehyde (MDA), medial forebrain bundle (MFB), middle cerebral artery occlusion (MCAO), minimal clonic seizures (MCS), nitric oxide (NO), pentylenetetrazole (PTZ), phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT), reactive oxygen species (ROS), retinal ganglion cells (RGCs), serum response factor (SRF), substantia nigra compacta (SNc), superoxide dismutase (SOD), streptozotocin (STZ), triglycerides (TG), tyrosine hydroxylase (TH), ventral tegmental area (VTA), and vascular endothelial growth factor receptor-2 (VEGFR-2).
Figure 2Illustrative scheme with different pathways of ROS formation and their impact on health. Bioactive compounds of Crocus sativus L. interfere with these mechanisms showing the beneficial effects for human health. Abbreviations and symbols: ↑ (increase, stimulate), ꓕ (decrease, inhibition), CAT (catalase), NO (nitric oxide), MDA (malondialdehyde), ROS (reactive oxidative species), glutathione peroxidase (GPx), GSSG (oxidized glutathione), GSH (reduced glutathione), O2− (superoxide), H2O2 (hydrogen peroxide), OH● (hydroxyl ions), and NO (nitric oxide).
Clinical studies.
| Type of extract | Type of study | Dose/period | Effect | References |
|---|---|---|---|---|
| Saffron extract | Randomized double-blind clinical trial | 30 mg/day | Saffron supplements statistically improved the mood of subjects compared to the placebo group based on the Hamilton depression rating scale (HAM-D) | [ |
| Saffron extract | Randomized double-blind clinical trial | 30 mg/day for six weeks | Treatment of mild to moderate depression | [ |
| Hydroalcoholic extract of | Randomized double-blind clinical trial | (40 or 80 mg) |
| [ |
| Crocin/aqueous extract | Clinical trial | 15 mg twice daily | Well tolerated by schizophrenic patients with no severe side effects | [ |
| Saffron extract (Affron®) | Randomized, double-blind, placebo-controlled study, youth aged 12–16 years | 14 mg twice daily | Improved anxiety and depressive symptoms | [ |
Figure 3The role of Crocus plants' phytoconstituents in the pharmacotherapeutic management of various disorders and the possible molecular mechanisms of action. Abbreviations and symbols: ↑ increased, ↓ decreased, acetylcholinesterase (AChE), alkaline phosphatase (ALP), aspartate transaminase (AST), catalase (CAT), creatine kinase (CK), glutathione (GSH), lactate dehydrogenase (LDH), noradrenaline (NA), poly (ADP-ribose) polymerase (PARP), reactive oxygen species (ROS), serum response factor (SRF), superoxide dismutase (SOD), tumor protein P53 (p53), tyrosine hydroxylase (TH), vascular endothelial growth factor receptor-2 (VEGFR-2), and very-low-density lipoprotein (VLDL).
Toxicological studies of Crocus sativus L.
| Extract/compound | Doses |
| Route of administration | Model | Adverse effects | Ref. |
|---|---|---|---|---|---|---|
| Aqueous extract | 1.2-2 g/bw |
| Intraperitoneal | Mice | Nausea, vomiting, diarrhea, bleeding | [ |
| Aqueous extract | 4 g/bw daily |
| Oral | Mice | Nontoxic | [ |
| Aqueous extract | IC50 = 50 − 400 mg/mL |
| — | CCD-18Lu | Noncytotoxic | [ |
| Aqueous extract | 500, 1000, and 2000 mg/kg daily saffron, three weeks |
| Oral | Mice | LD50 = 4120 mg/kg | [ |
| Aqueous extract | 50, 100, and 200 mg/kg |
| Intraperitoneal | Rats | Prevented the toxicity induced by diazinon in rats | [ |
| Ethanol extract stigmas | 0.35, 0.70, 1.05 g/kg daily |
| Intraperitoneal | Rats | ↓Hb, ↓HCT, ↓RBC | [ |
| Ethanol extract | 2 mg/kg of cisplatin |
| Oral | Mice | ↑life span of cisplatin-treated mice almost threefold | [ |
| Aqueous extract | 25-100 mg/kg |
| Intraperitoneal | Rats | ↑survival | [ |
| Aqueous extract | Several doses |
| Oral | Rats | 21.42 mL/kg | [ |
| Aqueous extract | Several doses |
| Intraperitoneal | Rats | 1.48 mL/kg | |
| Aqueous extract | Several doses |
| Oral | Mice | 5.53 mL/kg | |
| Aqueous extract | Several doses |
| Intraperitoneal | Mice | 3500 mg/kg | |
| Total extract | 0.35, 0.70, and 1.05 g/kg |
| Intraperitoneal | Rats | Hepatic, renal tissue damages anemia | [ |
| Crocetin | 10, 25, 50, 100, and 200 mM |
| — | Frog ( | Crocetin is a teratogen, but less potent than ATRA | [ |
| Safranal | 0.1, 0.5, 1 mL/kg |
| Intraperitoneal | Rats | Showed important toxicity than other active constituents in saffron stigma | [ |
| Safranal | 1.2 mL/kg |
| Intraperitoneal | Rats | ↓cytotoxicity | [ |
| Safranal | 1.2 mL/kg |
| Intraperitoneal | Mice | LD50 = 1.48 mL/kg | [ |
| Safranal | 1.2 mL/kg |
| Intraperitoneal | Mice | LD50 = 1.88 mL/kg | |
| Safranal | 1.2 mL/kg |
| Intraperitoneal | Rats | LD50 = 1.50 mL/kg | |
| Safranal | 1.2 mL/kg |
| Oral | Mice | LD50 = 21.42 mL/kg in | |
| Safranal | 1.2 mL/kg |
| Oral | Mice | LD50 = 11.42 mL/kg | |
| Safranal | 1.2 mL/kg |
| Oral | Rats | LD50 = 5.53 mL/kg | |
| Crocin | 150-210 g |
| Oral, intraperitoneal | Mice | ↑platelets, ↑creatinine | [ |
Abbreviations and symbols: ↑ increase, ↓ decrease, ALT (alanine aminotransferase), AST (aspartate transaminase), ATRA (all-trans retinoic acid), Hb (hemoglobin), HCT (hematocrit), and RBC (red blood cell).